Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This case report describes hair loss associated with olanzapine use, which resolved after discontinuation of the drug, highlighting potential reversible alopecia with atypical antipsychotics.

This article discusses the importance of increasing awareness about specific adverse drug reactions, prevention methods, and the promotion of reporting ADRs to the FDA's MEDWATCH program; it reports no new results.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Pramipexole can cause side effects like dizziness, sleepiness, hallucinations, and low blood pressure, and it's important to educate patients and keep doses low.

This article describes an increase in the detection of heart failure among young people and discusses the development of the drug Uperio for its treatment and support.

This study found that adults with type 2 diabetes or obesity using semaglutide and tirzepatide experienced higher odds of nonscarring alopecia, such as telogen effluvium, compared to those using other GLP-1 receptor agonists, with hair loss potentially linked to physiologic stress from weight loss.

This review highlights concerns about dermatological side effects linked to rapid weight loss from glucagon-like peptide-1 receptor agonists used for type 2 diabetes and obesity treatment, such as skin laxity, decreased collagen, and hair loss, emphasizing the importance of managing these while retaining metabolic benefits.

In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.

This case report presents an instance of acute pancreatitis following the use of ocrelizumab and suggests that its B lymphocyte suppression may contribute to pancreatitis by affecting cytokine release and T lymphocyte regulation.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This study highlights the approval of orforglipron under the FDA's National Priority Voucher program, emphasizing its significance as a convenient oral treatment option with beneficial effects on glycemic and lipid profiles for diabetes and obesity management.

This case report suggests that long-acting injectable risperidone may induce hirsutism in some patients, and clinicians should monitor for this potential side effect when prescribing this antipsychotic.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

This study found that finasteride reduced impulsivity in a rat model of pramipexole-induced probability discounting, possibly by normalizing D3 receptor expression in the nucleus accumbens.

This review discusses the roles and therapeutic effects of GLP-1 receptor agonists on the nervous, cardiovascular, and endocrine systems, but reports no new clinical results, emphasizing the need for further research on their impact on metabolism and tumor relationships in type 2 diabetes patients.

In this randomized trial, metformin and pioglitazone both improved certain clinical and metabolic indices in women with PCOS, with pioglitazone showing potential as an alternate treatment for those intolerant to metformin.

In this study, patient-reported outcomes indicated that greater weight loss with GLP-1RA treatments was associated with increased reports of adverse cosmetic effects such as skin laxity, facial volume loss, and hair shedding, despite improvements in some preexisting inflammatory skin conditions.

This case study observed that discontinuing risperidone reduced elevated prolactin levels and improved hair thinning in a 77-year-old woman, suggesting risperidone-associated telogen effluvium as a consideration in similar cases.

Tirzepatide may improve hair loss by reducing insulin resistance.

In this study, analysis of electronic health records suggested that patients taking semaglutide were significantly less likely to experience suicidal ideation compared to those on non-GLP-1 obesity or diabetes medications.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.

In this study, divalproex sodium extended-release was found to be more tolerable and preferred by patients compared to the delayed-release formulation, with improved seizure control and psychiatric symptom relief.

In this study, researchers explored drug repurposing as a potential strategy for treating psoriasis and identified Pioglitazone, Trimipramine, and Dimetindene as promising candidates for this indication, based on molecular docking and predictive algorithms.

GLP-1 and GLP-1/GIP agonists may increase the risk of hair loss.